Featured Editorial

1. How Should We Measure The True Potency Of RNA Therapeutics? 10/5/2026

   An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.

2. Engineering RNA Agonists For Systemic Immunity Without Systemic Toxicity 10/1/2026

   Krieg believes the answer lies in a deeper understanding of innate immune biology and the design of RNA/DNA hybrid mimics of viral RNA and DNA that are detected by innate immune receptors.

3. From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery? 9/23/2026

   We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies.

4. Is mRNA Manufacturing Overbuilt? 9/15/2026

   mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.

5. Why RNA–LNP Development Needs Higher-Resolution Analytics In 2027 9/11/2026

   Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential.

6. Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery 9/9/2026

   We discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.

7. What Oligo Manufacturing Risks Are We Underestimating? 9/8/2026

   Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. 

8. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

9. RNA Oligonucleotide Synthesis: How Advanced Manufacturing Technologies Are Accelerating Innovation 9/3/2026

   From a tech perspective, the manufacturing objective is shifting toward integrated process optimization. Automated reaction control, multivariate analytics, and more can connect molecular quality with operational performance. 

10. AI Agents Are Only As Good As The RNA Knowledge Behind Them 9/3/2026

    The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent.